Claims for Patent: 7,473,686

Summary for Patent: 7,473,686

Title:	Thrombopoietin mimetics
Abstract:	Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Inventor(s):	Duffy; Kevin J. (Collegeville, PA), Erickson-Miller; Connie (King Of Prussia, PA), Jenkins; Julian (Collegeville, PA), Luengo; Juan I. (Collegeville, PA), Visonneau; Sophie (Collegeville, PA)
Assignee:	SmithKline Beecham Corp. (Philadelphia, PA)
Application Number:	11/650,651
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,473,686
Patent Claims:	1. The compound: 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid, or a pharmaceutically acceptable salt thereof. 2. The compound 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-yliden- e]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid, or an ester thereof. 3. A compound of claim 2, wherein the compound is in the form of an ester. 4. A pharmaceutical composition which comprises a compound of claim 1 and a pharmaceutically acceptable carrier. 5. A pharmaceutical composition which comprises a compound of claim 2 and a pharmaceutically acceptable carrier. 6. A method of therapeutic therapy of thrombocytopenia in a human in need thereof which comprises administering to such human a therapeutically effective amount of a compound of claim 1. 7. The method of claim 6 wherein the compound is administered orally. 8. The method of claim 6 wherein the compound is administered parenterally. 9. The method of claim 6 further comprising co-administering a therapeutically effective amount of an agent selected from the group consisting of: a colony stimulating factor, cytokine, chemokine, and an interleukin or cytokine receptor agonist or antagonist. 10. The method of claim 9 wherein the agent is selected from the group consisting of: G-CSF, GM-CSF, TPO, M-CSF, EPO, Gro-beta, IL-11, SCF, FLT3 ligand, LIF, IL-3, IL-6, IL-1, NESP, SD-01, IL-8, and IL-5. 11. The method of claim 10 wherein the agent is selected from the group consisting of: G-CSF, GM-CSF, TPO, M-CSF, EPO, and IL-11. 12. The method of claim 6 wherein said thrombocytopenia is due to myelosuppression caused by chemotherapy or radiation therapy. 13. The method of claim 6 wherein said thrombocytopenia is due to an organ transplant. 14. The method of claim 6 wherein said thrombocytopenia is due to bone marrow, stem cell, or liver transplant. 15. The method of claim 6 wherein said thrombocytopenia is due to idiopathic thrombocytopenia purpura (ITP). 16. The method of claim 6 wherein said thrombocytopenia is due to myelodysplastic syndromes (MDS), aplastic anemia or leukemia. 17. The method of claim 6 wherein said thrombocytopenia is due to viral, fungal, microbial or parasitic infection. 18. The method of claim 6 wherein said thrombocytopenia is due to liver dysfunction. 19. The method of claim 6 wherein said thrombocytopenia is due to surgical procedures. 20. The method of claim 6 wherein said thrombocytopenia is due to treatment with antiviral or antibiotic agents. 21. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound of claim 1, which process comprises bringing said compound into association with the pharmaceutically acceptable carrier or diluent. 22. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound of claim 2, which process comprises bringing said compound into association with the pharmaceutically acceptable carrier or diluent. 23. The method of claim 6 wherein said thrombocytopenia is due to exposure to radiation. 24. The method of claim 6 wherein said thrombocytopenia is due to treatment with antiviral agents. 25. The method of claim 6 wherein said thrombocytopenia is due to treatment with antibiotic agents.